

May 21, 2009
Mitsubishi Tanabe Pharma Corporation

**Approval Acquired for Additional Indication for the Anti-Cytomegalovirus
Chemotherapeutic Agent Valixa® Tablet 450 mg for Cytomegalovirus Infection in Organ
Transplantation (including hematogenic stem cell transplantation) and Malignant Tumor**

Mitsubishi Tanabe Pharma Corporation (Osaka, President: Natsuki Hayama) hereby announce that the Company obtained approval on May 20 for an additional indication for cytomegalovirus infection in organ transplantation (including hematogenic stem cell transplantation) and malignant tumor for the anti-cytomegalovirus chemotherapeutic agent Valixa® Tablet 450 mg (generic name: valganciclovir hydrochloride; manufactured and marketed by Mitsubishi Tanabe Pharma Corporation), meaning that the indication for Valixa Tablet 450 mg has changed from “treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome (AIDS)”, which it has been until now, to “cytomegalovirus infection in acquired immune deficiency syndrome, organ transplantation (including hematogenic stem cell transplantation) and malignant tumor.

Cytomegalovirus (CMV) is a classic opportunistic pathogen virus. It is said that almost all Japanese are infected with CMV soon after birth and carry CMV throughout their lives (lungs, digestive tract, liver, etc) in a state of latent infection.

Due on the one hand to the use of strong immunosuppressive agents in recent years, clinical results for organ transplantation have improved markedly, but on the other, the immunodeficient conditions triggered by the use of those immunosuppressive agents has induced opportunistic infections (CMV infections, etc) and development into fatal infection disease has not been rare.

In Japan, Denosine® 500 mg for I.V. Infusion, which Mitsubishi Tanabe Pharma manufactures and markets, is used as an anti-cytomegalovirus chemotherapeutic agent for CMV infection after organ transplantation, but the burden placed on the patient is large because the agent is administered by I.V. infusion and a preparation enabling oral administration has been hoped for.

For this reason, Mitsubishi Tanabe Pharma Corporation commenced clinical trials for the oral agent Valixa® Tablet 450 mg from 2006 and as a result, the Company applied for approval of the additional indications in June 2008 because the strong effects of this agent were confirmed in organ transplantation patients.

Mitsubishi Tanabe Pharma Corporation will be able to provide this therapeutic agent enabling oral administration to CMV infection patients in Japan due to the recently-obtained approval for these additional indications and believes that the Company can contribute further to unmet medical needs in clinical practice.